Literature DB >> 18313916

Role of FDG PET in the management of childhood lymphomas--case proven or is the jury still out?

Ananth Shankar1, Frank Fiumara, Ross Pinkerton.   

Abstract

Positron emission tomography (PET) is a novel non invasive functional imaging modality that is increasingly used for the primary staging of lymphomas and assessment of therapeutic response. This review evaluates the published reports of its use in childhood lymphomas, particularly in the primary staging, response assessment and monitoring after completion of treatment. Specific attention is focused on the clinical circumstances in which FDG PET is most likely to have an impact on management and some indications for its use in childhood lymphomas are suggested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313916     DOI: 10.1016/j.ejca.2008.02.005

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Staging of common paediatric tumours.

Authors:  Hervé J Brisse
Journal:  Pediatr Radiol       Date:  2009-06

2.  FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.

Authors:  Egesta Lopci; Maurizio Mascarin; Arnoldo Piccardo; Angelo Castello; Caterina Elia; Luca Guerra; Eugenio Borsatti; Alessandra Sala; Alessandra Todesco; Pietro Zucchetta; Piero Farruggia; Angelina Cistaro; Salvatore Buffardi; Patrizia Bertolini; Maurizio Bianchi; Maria Luisa Moleti; Feisal Bunkheila; Paolo Indolfi; Franca Fagioli; Alberto Garaventa; Roberta Burnelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-15       Impact factor: 9.236

3.  Altered FDG uptake patterns in pediatric lymphoblastic lymphoma patients receiving induction chemotherapy that includes very high dose corticosteroids.

Authors:  Susan E Sharp; Michael J Gelfand; Michael J Absalon
Journal:  Pediatr Radiol       Date:  2011-09-01

4.  Revised International Pediatric Non-Hodgkin Lymphoma Staging System.

Authors:  Angelo Rosolen; Sherrie L Perkins; C Ross Pinkerton; R Paul Guillerman; John T Sandlund; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

5.  International Pediatric Non-Hodgkin Lymphoma Response Criteria.

Authors:  John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

6.  The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.

Authors:  Deepa Bhojwani; Mary B McCarville; John K Choi; Jennifer Sawyer; Monika L Metzger; Hiroto Inaba; Andrew M Davidoff; Robert Gold; Barry L Shulkin; John T Sandlund
Journal:  Br J Haematol       Date:  2014-11-10       Impact factor: 6.998

7.  Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease.

Authors:  Egesta Lopci; Roberta Burnelli; Luca Guerra; Angelina Cistaro; Arnoldo Piccardo; Pietro Zucchetta; Enrico Derenzini; Alessandra Todesco; Alberto Garaventa; Fabio Schumacher; Piero Farruggia; Salvatore Buffardi; Alessandra Sala; Fiorina Casale; Paolo Indolfi; Samanta Biondi; Andrea Pession; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

8.  PET/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients.

Authors:  Suyun Chen; Shaoyan Wang; Kejun He; Chao Ma; Hongliang Fu; Hui Wang
Journal:  Eur Radiol       Date:  2018-01-30       Impact factor: 5.315

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.